Antibodies to watch in 2016

mAbs

Volumn 8, Issue 2, 2016, Pages 197-204

  Reichert, Janice M ^a  

^a Reichert Biotechnology Consulting LLC   (United States)

Author keywords

Antibody therapeutics; Clinical studies; Drug development; European medicines agency; Food and drug administration

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY;

HUMAN; NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS;

EID: 84964523414     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1125583     Document Type: Article

References (11)

1. ReichertJM.Antibodies to watch in 2015. MAbs2015; 7:1-8; PMID:25484055; http://dx.doi.org/10.4161/19420862.2015.988944.
2. ReichertJM.Antibodies to watch in 2010. MAbs2010; 2:84-100; PMID:20065640; http://dx.doi.org/10.4161/mabs.2.1.10677.
3. ReichertJM.Marketed therapeutic antibodies compendium. MAbs2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/ mabs.19931.
4. LonialS, DimopoulosM, PalumboA, WhiteD, GrosickiS, SpickaI, Walter-CroneckA, MoreauP, MateosMV, MagenH, et al.ELOQUENT- 2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med2015; 373:621-31; PMID:26035255; http://dx.doi.org/10.1056/NEJMoa1505654.
5. LebwohlM, StroberB, MenterA, GordonK, WeglowskaJ, PuigL, PappK, SpelmanL, TothD, KerdelF, et al.Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med2015; 373:1318-28; PMID:26422722; http://dx.doi.org/10.1056/NEJMoa1503824.
6. GriffithsCE, ReichK, LebwohlM, van de KerkhofP, PaulC, MenterA, CameronGS, EricksonJ, ZhangL, SecrestRJ, et al.UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet2015; 386:541-51; PMID:26072109; http://dx.doi.org/10.1016/ S0140-6736(15)60125-8.
7. CastroM, ZangrilliJ, WechslerME, BatemanED, BrusselleGG, BardinP, MurphyK, MasperoJF, O’BrienC, KornS.Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-βlind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med2015; 3:355-366; PMID:25736990; http://dx.doi.org/10.1016/S22132600(15)00042-9.
8. GenoveseMC, FleischmannR, KivitzAJ, Rell-βakalarskaM, MartincovaR, FioreS, RohaneP, van HoogstratenH, GargA, FanC, et al.Sarilumab plus methotrexate in patients with active rheumatoid arthritis and Inadequate response to methotrexate: Results of a Phase III study. Arthritis Rheumatol2015; 67:1424-37; PMID:25733246; http://dx.doi.org/10.1002/art.39093.
9. GordonKB, DuffinKC, BissonnetteR, PrinzJC, WasfiY, LiS, ShenYK, SzaparyP, RandazzoB, ReichK.A Phase 2 trial of guselkumab vs. adalimumab for plaque psoriasis. N Engl J Med2015; 373:136-144; PMID:26154787; http://dx.doi.org/10.1056/ NEJMoa1501646.
10. BallantyneCM, NeutelJ, CroppA, DugganW, WangEQ, PlowchalkD, SweeneyK, KailaN, VincentJ, BaysH.Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol2015; 115:1212-21; PMID:25784512; http://dx.doi.org/10.1016/j.amjcard. 2015.02.006.
11. KruegerJG, FerrisLK, MenterA, WagnerF, WhiteA, VisvanathanS, LalovicB, AslanyanS, WangEE, HallD, SolingerA, PadulaS, SchollP.Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-βlind, placebo-controlled trial. J Allergy Clin Immunol2015; 136:116-124; PMID:25769911; http://dx.doi.org/10.1016/j.jaci.2015.01.018.